Compare Heron Therapeutics Inc (HRTX) vs NVR Inc. Common Stock (NVR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs NVR Inc. Common Stock — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $74.18M), while NVR Inc. Common Stock trades at $5,750 (market cap $15.45B). The key difference: NVR Inc. Common Stock is far larger — about 208.3× Heron Therapeutics Inc's market cap, and NVR Inc. Common Stock is more actively traded (53,419 versus 1,857,401). Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 36 Days and NVR Inc. Common Stock for 0 Days on average.
| HRTX | NVR | |
|---|---|---|
Market Cap | $74.18M | $15.45B |
Volume | 1,857,401 | 53,419 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.49 | $8.10K |
52-Week Low | $0.27 | $5.56K |
Typical Hold Time | 36 Days | 0 Days |
Enterprise Value | $180.92M | $15.36B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.3906, down 6.02% today, with a bullish technical signal from moving averages and oscillators. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates. Despite a high gross margin of 70.07%, it posted a net loss of -$20.20 million in 2025. Analyst consensus is strongly positive with 17 buy ratings. Recent news highlights earnings results and competitive comparisons.
The outlook remains speculative given persistent losses and negative ROE, but strong analyst support and improving cash flow trends offer potential upside. Key risks include profitability challenges and revenue volatility. Investors should weigh the bullish sentiment against fundamental weaknesses.
NVR trades at $5,797.61, up 0.83% today, with a P/E of 15.07 and P/S of 1.79. Recent earnings missed estimates in Q1 and Q2 2026, with revenue and net income projected to decline in 2026. The stock faces headwinds from margin pressure and softer homebuyer demand, as highlighted by Zacks naming it Bear of the Day on October 9, 2026. Despite this, strong profitability metrics like a 31.54% ROE and consistent cash flow from operations support its financial resilience.
The outlook is cautious due to earnings misses and a projected revenue drop, but the asset-light model and share buybacks provide stability. Risks include mortgage rate sensitivity and competitive pressures, while analyst consensus leans neutral with a $6,550 price target. Patient investors may find value if housing demand recovers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About NVR Inc. Common Stock
NVR Inc. is a homebuilder operating through homebuilding and mortgage banking segments, building single-family homes, townhomes, and condominiums under the Ryan Homes, NVHomes, and Heartland Homes brands. It uses a land-light model, acquiring lots through third-party option agreements rather than holding large land inventories, and provides mortgage and title services through NVR Mortgage.
Read more on NVR →
